BioXcel Therapeutics (BTAI) Cash from Investing Activities (2018 - 2022)

BioXcel Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$19000.0 for Q2 2022.

• In Q2 2022, Cash from Investing Activities rose 81.0% year-over-year to -$19000.0; the TTM figure through Sep 2023 stood at -$19000.0 (up 87.42% YoY), while the FY2023 annual figure was -$20000.0, up 85.61% from the prior year.
• Cash from Investing Activities was -$19000.0 for Q2 2022 at BioXcel Therapeutics, up from -$120000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $5000.0 in Q3 2020 to a low of -$600000.0 in Q1 2019.
• Historically, Cash from Investing Activities has averaged -$124375.0 across 5 years, with a median of -$52500.0 in 2018.
• Biggest YoY gain for Cash from Investing Activities was 111.63% in 2020; the steepest drop was 13400.0% in 2020.
• A 5-year view of Cash from Investing Activities shows it stood at -$158000.0 in 2018, then surged by 98.73% to -$2000.0 in 2019, then slumped by 13400.0% to -$270000.0 in 2020, then surged by 95.56% to -$12000.0 in 2021, then plunged by 58.33% to -$19000.0 in 2022.
• The last three Cash from Investing Activities figures came in at -$19000.0 (Q2 2022), -$120000.0 (Q1 2022), and -$12000.0 (Q4 2021), per Business Quant data.